The new approval will help Merck make a return on its $3.9 billion investment in acquiring SpringWorks, which has operated as ...

"While COPD remains the third leading cause of death worldwide, patients and families have limited treatment options for ...

Sarepta has refused to suspend all dosing of its gene therapy for Duchenne muscular dystrophy, Elevidys, defying a clinical ...

Using microneedle arrays developed at Carnegie Melon, microdosed with a known chemotherapeutic agent delivered directly to ...

Just over two years into Anderson's tenure, Bayer's board has decided to extend his contract by three years to 31st March ...

Engaging all stakeholders in the process of establishing a global MI service is key to its overall success. Each ...

The UK government has revealed a plan to open a biosecurity facility in Harlow, Essex, to help protect the country from ...

Hong Kong-based Sino Biopharm, which took its stake in LaNova when it participated in the company's $42 million financing ...

Kisqali was approved for the new indication on the back of the NATALEE trial, in which adding Kisqali to standard treatment ...

Sidders discusses how integrating causality in AI for biotechnology can drive greater R&D success, and more generally about ...

An antibody being developed by AstraZeneca for the treatment of light chain (AL) amyloidosis has failed to move the needle in ...

A third fatality has been recorded among patients receiving treatment with a Sarepta gene therapy, adding to the troubles ...